Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Urologix, Inc. (NasdaqNM:ULGX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug  9Conference call: Urologix Earnings (Q4 2001)
Aug  8Earnings Announcement
Location
14405 21st Avenue North
Minneapolis, MN 55447
Phone: (612) 475-1400
Fax: (612) 475-1443
Employees (last reported count): 72
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 30%
·Over the last 6 months:
 · 11 insider sells; 151.0K shares
  (3.7% of insider shares)
·Institutional: 57% (81% of float)
(91 institutions)
·Net Inst. Buying: 2.67M shares (+26.25%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Urologix, Inc. was organized to research, develop, manufacture and market innovative devices for the treatment of benign prostatic hyperplasia (BPH) and other urological disorders. The Company's Targis System is a non-surgical, catheter-based treatment for BPH that is better than medication and less invasive than surgery. The Targis System was developed to be the therapy of choice for patients for whom drugs have failed but who wish to avoid choosing surgery. The Targis System utilizes a proprietary microwave technology, delivered through a flexible catheter that precisely targets energy into the diseased area of the prostate to a temperature sufficient to cause cell death, while simultaneously cooling and protecting the pain sensitive urethral tissue.
More from Market Guide: Expanded Business Description

Financial Summary
Urologix, Inc. develops, manufactures and markets minimally invasive medical devices for the treatment of urological diseases. The Company's product, called Targis System, is designed to treat Benign Prostatic Hyperplasia. For the fiscal year ended 6/30/01, sales rose 88% to $15.3 million. Net loss fell 28% to $5.1 million. Revenues reflect higher demand for Targis and Prostatron systems from urologists. Net loss reflects costs related to the expansion of sales force.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 5,691; after tax earnings were -854. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Mitchell Dann, 40
Chairman
--  
Michael Selzer, Jr., 48
Pres, CEO, Director
$291K
Ronald Blasewitz, 51
Sr. VP, COO
150K
Christopher Geyen, 29
VP, CFO, Sec., Treasurer
136K
Kirsten Doerfert, 44
VP, Marketing
--  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ULGXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 12-Oct-2000
$6.875
Recent Price$14.85 
52-Week High
on 24-May-2001
$28.36 
Beta-0.60 
Daily Volume (3-month avg)241.5K
Daily Volume (10-day avg)116.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+74.7%
52-Week Change
relative to S&P500
+134.4%
Share-Related Items
Market Capitalization$195.5M
Shares Outstanding13.2M
Float9.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$2.82 
Earnings (ttm)-$0.40 
Earnings (mrq)-$0.06 
Sales (ttm)$1.18 
Cash (mrq*)$0.95 
Valuation Ratios
Price/Book (mrq*)5.27 
Price/EarningsN/A 
Price/Sales (ttm)12.58 
Income Statements
Sales (ttm)$15.3M
EBITDA (ttm*)-$6.25M
Income available to common (ttm)-$5.13M
Profitability
Profit Margin (ttm)-33.5%
Operating Margin (ttm)-59.8%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-13.53%
Return on Equity (ttm)-15.67%
Financial Strength
Current Ratio (mrq*)3.18 
Debt/Equity (mrq*)0.05 
Total Cash (mrq)$14.9M
Short Interest
As of 8-Aug-2001
Shares Short1.67M
Percent of Float18.2%
Shares Short
(Prior Month)
2.65M
Short Ratio5.37 
Daily Volume312.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.